1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical report: pri- mary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17 Suppl 4:iv1–iv62.
2. Brown TJ, Brennan MC, Li M, et al. Association of the extent of re- section with survival in Glioblastoma: a systematic review and meta- analysis. JAMA Oncol. 2016;2(11):1460–1469.
3. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8.
4. Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric per- spective on glioma invasion. Nat Rev Neurosci. 2014;15(7):455–465.
5. Scherer JH. Structural development in gliomas. Am J Cancer. 1938;34(3):333–351.
6. Montana V, Sontheimer H. Bradykinin promotes the chemotactic inva- sion of primary brain tumors. J Neurosci. 2011;31(13):4858–4867.
7. Amit M, Na’ara S, Gil Z. Mechanisms of cancer dissemination along nerves. Nat Rev Cancer. 2016;16(6):399–408.
8. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an over- view of proliferation and invasion. Neuro Oncol. 2014;16(12):1575–1584.
9. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. ‘Go or grow’: the key to the emergence of invasion in tumour progression? Math Med Biol. 2012;29(1):49–65.
10. Alfonso JC, Köhn-Luque A, Stylianopoulos T, Feuerhake F, Deutsch A, Hatzikirou H. Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights. Sci Rep. 2016;6:37283.
11. Miyai M, Tomita H, Soeda A, Yano H, Iwama T, Hara A. Current trends in mouse models of glioblastoma. J Neurooncol. 2017;135(3):423–432.
12. Mack SC, Hubert CG, Miller TE, Taylor MD, Rich JN. An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 2016;19(1):10–19.
13. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in his- tone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231.
14. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblas- toma. Cancer Cell. 2012;22(4):425–437.
15. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glio- blastomas. Nat Genet. 2012;44(3):251–253.
16. Krug B, De Jay N, Harutyunyan AS, et al. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M Gliomas. Cancer Cell. 2019;35(5):782–797 e788.
17. Chung C, Sweha SR, Pratt D, et al. Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell. 2020;38(3):334–349 e339.
18. Plessier A, Le Dret L, Varlet P, et al. New in vivo avatars of diffuse in- trinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget. 2017;8(32):52543–52559.
19. Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular sub- groups and recurrent activating ACVR1 mutations. Nat Genet. 2014;46(5):451–456.
20. Ohtani K, Suzumura A, Sawada M, Marunouchi T, Nakashima I, Takahashi A. Establishment of mouse oligodendrocyte/type-2 astrocyte lineage cell line by transfection with origin-defective simian virus 40 DNA. Cell Struct Funct. 1992;17(5):325–333.
21. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment anal- ysis: a knowledge-based approach for interpreting genome-wide ex- pression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550.
22. Hailesellasse Sene K, Porter CJ, Palidwor G, et al. Gene function in early mouse embryonic stem cell differentiation. BMC Genomics. 2007;8:85.
23. Adam J, Yang M, Soga T, Pollard PJ. Rare insights into cancer biology. Oncogene. 2014;33(20):2547–2556.
24. Lee JV, Berry CT, Kim K, et al. Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca2+-NFAT signaling. Genes Dev. 2018;32(7-8):497–511.
25. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
26. Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26(9):877–890.
27. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408.
28. Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017;23(4):493–500.
29. Roos A, Ding Z, Loftus JC, Tran NL. Molecular and microenvironmental determinants of Glioma stem-like cell survival and invasion. Front Oncol. 2017;7:120.
30. Shaver MM, Kohanteb PA, Chiou C, et al. Optimizing neuro-oncology imaging: a review of deep learning approaches for glioma imaging. Cancers (Basel). 2019;11(6):829.
31. Nakata R, Hyodo F, Murata M, et al. In vivo redox metabolic im- aging of mitochondria assesses disease progression in non-alcoholic steatohepatitis. Sci Rep. 2017;7(1):17170.
32. Hyodo F, Matsumoto K, Matsumoto A, Mitchell JB, Krishna MC. Probing the intracellular redox status of tumors with magnetic res- onance imaging and redox-sensitive contrast agents. Cancer Res. 2006;66(20):9921–9928.
33. Granchi C, Minutolo F. Anticancer agents that counteract tumor glycol- ysis. Chemmedchem. 2012;7(8):1318–1350.
34. Wu Q, Ba-Alawi W, Deblois G, et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat Commun. 2020;11(1):4205.
35. Devraj K, Klinger ME, Myers RL, Mokashi A, Hawkins RA, Simpson IA. GLUT-1 glucose transporters in the blood-brain barrier: differential phos- phorylation. J Neurosci Res. 2011;89(12):1913–1925.